Sign inJoin waitlistJoin the waitlist

Mothaffar Rimawi

Clinical Science Leader) · Baylor College of Medicine

Credentials: · · · ·

History

Baylor College of Medicine
Present

Baylor College of Medicine
2000–2002
Internal Medicine
1997–2000
Doctor of Medicine
1993–1997

Research

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Journal of Clinical Oncology · 2012 · 416 citations
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Cancer Research · 2008 · 386 citations
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
Cancer Research · 2013 · 381 citations

Kent Osborne
55 papers
AW
Antonio Wolff
29 papers
IK
Ian Krop
28 papers
Eric Winer
21 papers
JN
Julie Nangia
15 papers
Lisa Carey
14 papers
Rita Nanda
14 papers
Vandana Abramson
13 papers
ME
Matthew Ellis
12 papers
Hope Rugo
11 papers
Jen-Yun Chang
11 papers · 1 as a resident
ML
Minetta Liu
11 papers

Grants

Translational Research in Breast Cancer
National Cancer Institute · P50
PI · $2M · Baylor College of Medicine
2014–2025
Translational Breast Cancer Research Training Program
National Cancer Institute · T32
PI · $400.9K · Baylor College of Medicine
2018–2024
NSABP Participating Sites
National Cancer Institute · U10
Contact PI · $175.8K · Baylor College of Medicine
2006–2013

Clinical trials

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Principal investigator · Recruiting · Phase 2
Baylor Breast Care Center
2023–2029
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Principal investigator · Recruiting · Phase 3
Greenwich LifeSciences, Inc.
2022–2031
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
Principal investigator · Active not recruiting · Phase 2
Baylor Breast Care Center
2020–2030
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Principal investigator · Completed · Phase 1, Phase 2
Orinove, Inc.
2019–2023